Study of tacabrutideg for chronic spontaneous urticaria
Part of Immune system & allergy, Skin clinical trials.
This trial tests a new oral medication called tacabrutideg (BGB-16673) for chronic spontaneous urticaria, a condition with frequent hives and itching. It aims to see how safe it is and how well it works, possibly offering a new option for people who still have symptoms despite antihistamines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have chronic spontaneous urticaria (CSU) for at least 6 months.
- You must have had itching and hives for at least 6 weeks in a row, even while taking antihistamines.
- You must not have a clear trigger for your hives (like cold, heat, pressure, or sunlight).
- You must not have certain other skin conditions that cause itching (like psoriasis or atopic dermatitis).
- You must not have taken any BTK inhibitor or protein degrader before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new injectable medicine (JYB1904) to see if it can reduce itching and hives better than standard antihistamines alone. If you have chronic hives with no clear cause and still get symptoms despite taking antihistamines, this study may be an option for you.
This trial tests a new medicine, JYB1904, for people with chronic hives (itching and welts) that haven't been controlled by standard allergy pills. It aims to see if JYB1904 can reduce itching and hives better.
This trial tests a new medicine called BBT001 for people with chronic spontaneous urticaria (long-lasting hives without a known cause). It aims to see if the drug is safe and helps reduce itching and hives.
This trial tests a treatment plan using remibrutinib (a pill) and omalizumab (a biologic shot) for adults with chronic spontaneous urticaria (chronic hives) that are not well controlled by antihistamines. The goal is to see if this combination can reduce itching and hives better than current options.
This study tests an experimental capsule (HS-10561) to see if it is safe and works for people with chronic spontaneous urticaria, which causes hives and itching without a clear trigger. If you have had hives for at least 6 months, you might be able to join.
This program offers remibrutinib, an experimental oral medication, to adults with chronic spontaneous urticaria (long-lasting hives without a known trigger) that hasn't improved with standard antihistamines or omalizumab. It aims to see if this drug can reduce symptoms when other options haven't worked.
Hear when a new Chronic Spontaneous Urticaria trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.